Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GBSNASDAQ:ICCMNYSE:NSPRNASDAQ:NVNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBSGBS$1.41+9.3%$1.40$0.36▼$2.89$21.00M1.32955,325 shs148,183 shsICCMIceCure Medical$1.06+3.9%$1.13$0.48▼$1.66$58.83M0.41470,336 shs133,179 shsNSPRInspireMD$2.53+11.0%$2.56$2.07▼$3.80$77.51M0.6238,006 shs38,347 shsNVNOenVVeno Medical$3.35-2.0%$2.92$2.03▼$6.48$58.75M0.8113,199 shs46,949 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBSGBS+2.79%+4.03%+4.03%-41.63%-44.16%ICCMIceCure Medical+3.92%+1.92%-5.36%-24.82%0.00%NSPRInspireMD+10.96%+7.20%-2.32%-20.69%+4.16%NVNOenVVeno Medical-2.05%-7.46%+25.47%-11.14%-32.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGBSGBSN/AN/AN/AN/AN/AN/AN/AN/AICCMIceCure Medical2.0621 of 5 stars3.83.00.00.01.90.00.6NSPRInspireMD2.1057 of 5 stars3.50.00.00.01.52.50.6NVNOenVVeno Medical0.739 of 5 stars0.02.00.00.02.50.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGBSGBS 0.00N/AN/AN/AICCMIceCure Medical 3.50Strong Buy$2.50135.85% UpsideNSPRInspireMD 3.00Buy$4.5077.87% UpsideNVNOenVVeno Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GBS, NSPR, NVNO, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.003/28/2025ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGBSGBS$440K47.72N/AN/A$0.44 per share3.20ICCMIceCure Medical$3.29M17.88N/AN/A$0.27 per share3.93NSPRInspireMD$7.03M11.03N/AN/A$1.83 per share1.38NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGBSGBS-$8.31M-$0.56N/AN/AN/AN/A-85.64%-54.42%N/AICCMIceCure Medical-$14.65M-$0.30N/AN/AN/A-376.85%-124.44%-87.70%5/28/2025 (Estimated)NSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ANVNOenVVeno Medical-$23.52M-$1.18N/AN/AN/AN/A-48.72%-45.96%7/30/2025 (Estimated)Latest GBS, NSPR, NVNO, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2025Q1 2025ICCMIceCure Medical-$0.08N/AN/AN/A$0.75 millionN/A4/30/2025Q1 2025NVNOenVVeno MedicalN/A-$0.22N/A-$0.22N/AN/A3/27/2025Q4 2024ICCMIceCure Medical-$0.07-$0.08-$0.01-$0.08$1.07 million$1.07 million2/27/2025Q4 2024NVNOenVVeno Medical-$0.35-$0.30+$0.05-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGBSGBSN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGBSGBSN/A2.332.33ICCMIceCure Medical0.022.672.27NSPRInspireMDN/A6.396.05NVNOenVVeno MedicalN/A22.0122.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGBSGBS2.79%ICCMIceCure Medical0.62%NSPRInspireMD44.78%NVNOenVVeno Medical34.71%Insider OwnershipCompanyInsider OwnershipGBSGBS0.27%ICCMIceCure Medical2.44%NSPRInspireMD29.72%NVNOenVVeno Medical16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGBSGBS714.89 million14.85 millionNot OptionableICCMIceCure Medical6055.50 million54.15 millionNot OptionableNSPRInspireMD5030.64 million18.33 millionOptionableNVNOenVVeno Medical1917.54 million14.73 millionOptionableGBS, NSPR, NVNO, and ICCM HeadlinesRecent News About These CompaniesEnVVeno Medical Names Jennifer Bright as CFOMay 19, 2025 | ocbj.comenVVeno Medical Appoints Jennifer Bright as Chief Financial OfficerMay 19, 2025 | accessnewswire.comEnVVeno has first-in-human heart valve data, expects FDA decision this yearMay 14, 2025 | massdevice.comThree-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular SurgeryMay 13, 2025 | accessnewswire.comAlyeska Investment Group L.P. Trims Position in enVVeno Medical Corporation (NASDAQ:NVNO)May 9, 2025 | marketbeat.comenVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24May 1, 2025 | accessnewswire.comVenoValve to be Featured During Presentation at the 47th Annual Charing Cross SymposiumApril 23, 2025 | accessnewswire.comenVVeno Medical Corp appoints CBIZ CPAs as new auditorApril 23, 2025 | investing.comenVVeno Medical to Participate in a Live Virtual Investor Closing Bell SegmentApril 16, 2025 | accessnewswire.comAnalysis of SAVVE Pivotal Trial Data Presented for enVVeno VenoValveApril 15, 2025 | evtoday.comThe Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual SymposiumMarch 31, 2025 | accessnewswire.comenVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last yearMarch 1, 2025 | markets.businessinsider.comenVVeno Medical files $100M mixed securities shelfMarch 1, 2025 | markets.businessinsider.comenVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25February 28, 2025 | accessnewswire.comenVVeno Medical presents one-year data from VenoValve trialFebruary 20, 2025 | markets.businessinsider.comOne-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators.February 19, 2025 | kansascity.comenVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | accessnewswire.comOne-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous ForumFebruary 19, 2025 | accessnewswire.comVenoValve trial shows sustained patient benefits at 24 monthsFebruary 7, 2025 | msn.comenVVeno Medical presents two-year follow-up data from VenoValve trialFebruary 7, 2025 | markets.businessinsider.comInterim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter MeetingFebruary 7, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGBS, NSPR, NVNO, and ICCM Company DescriptionsGBS NYSE:GBS$1.41 +0.12 (+9.30%) As of 05/23/2025GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.IceCure Medical NASDAQ:ICCM$1.06 +0.04 (+3.92%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.06 +0.00 (+0.47%) As of 05/23/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.InspireMD NYSE:NSPR$2.53 +0.25 (+10.96%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.44 -0.09 (-3.56%) As of 05/23/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.enVVeno Medical NASDAQ:NVNO$3.35 -0.07 (-2.05%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
